AGP Executive Report
Last update: 10 hours agoSleep & Heart Risk: New research links obstructive sleep apnea to cardiovascular harm via inflammation, oxidative stress, and circadian clock disruption. Biotech Manufacturing: Dark Horse Consulting Group and Altruist Biologics plan to streamline global biologics development and cGMP manufacturing in China. Diagnostics Expansion: ABL Diagnostics is rolling out HybridChek, combining amplicon and hybrid capture sequencing for HIV and tuberculosis whole-genome testing. Cancer Drug Delivery: Sanofi’s Sarclisa gets EU approval in a subcutaneous on-body injector format for multiple myeloma, aiming to reduce clinic burden. Targeted Drug Pipeline: Amphista’s IND for AMX-883 clears, setting up a Phase 1 trial in relapsed/refractory AML and high-risk MDS. Company Deal: Japan’s GNI Group will buy Ayumi Pharmaceutical from Blackstone in a ~$280M deal to expand its pain-management and rheumatology footprint. Nursing Home Watch (CMS): CMS ratings highlight wide variation in Q1 2026 performance, from 5-star Kensington Health & Rehabilitation to 1-star Village Health Care Center. Wellness Industry: Aker BioMarine kicks off Vitality Month 2026 in Frankfurt with a brain-health and healthy-ageing program. Public Health Pressure: Bangladesh faces a dengue surge alongside a major measles outbreak, straining hospitals and pediatric care. Health Tech & Data: A guide spotlights Apple Health–Google Health integration for cross-platform tracking, while a separate study uses whole-body PET/CT to map metabolic changes after bariatric surgery.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
